Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Minimally Invasive Therapy & Allied Technologies : MITAT : Official Journal of the Society for Minimally Invasive Therapy|March 15, 2021
Irradiation stent insertion for distal biliary obstruction secondary to primary common biliary cancerBing-Yan Zhu, Dong-Kai Chen, Hong-Hua Yin, et al.
Chemical & Pharmaceutical Bulletin|September 2, 2009
Design, synthesis and discovery of 1-(2-(6-Chloro-3-methylsulfonyl)-naphthyl)-1H-pyrazole-5-carboxylamides as highly potent factor Xa inhibitorsZhaozhong Jon Jia, Robert Murry Scarborough, Penglie Zhang, et al.
Oncotarget|January 21, 2017
A new HDAC inhibitor cinnamoylphenazine shows antitumor activity in association with intensive macropinocytosisBing-Yan Zhu, Bo-Yang Shang, Yue Du, et al.
Bioorganic & Medicinal Chemistry Letters|March 18, 2003
Design, synthesis, and structure-activity relationships of substituted piperazinone-based transition state factor Xa inhibitorsTing Su, Hua Yang, Deborah Volkots, et al.
Bioorganic & Medicinal Chemistry Letters|March 20, 2009
Anthranilamide-based N,N-dialkylbenzamidines as potent and orally bioavailable factor Xa inhibitors: P4 SARPenglie Zhang, Liang Bao, Jingmei Fan, et al.
Bioorganic & Medicinal Chemistry Letters|December 17, 2002
Design and synthesis of factor Xa inhibitors and their prodrugsYonghong Song, Lane Clizbe, Chhaya Bhakta, et al.
Bioorganic & Medicinal Chemistry Letters|July 13, 2002
Substituted acrylamides as factor Xa inhibitors: improving bioavailability by P1 modificationYonghong Song, Lane Clizbe, Chhaya Bhakta, et al.
Bioorganic & Medicinal Chemistry Letters|August 26, 2006
Inhibitory effect of carboxylic acid group on hERG bindingBing-Yan Zhu, Zhaozhong J Jia, Penglie Zhang, et al.
Bioorganic & Medicinal Chemistry Letters|March 18, 2003
Design, synthesis, and structure-activity relationships of unsubstituted piperazinone-based transition state factor Xa inhibitorsWenrong Huang, Mary Ann Naughton, Hua Yang, et al.
Pharmacological Research|April 11, 2017
Recombinant EGFR/MMP-2 bi-targeted fusion protein markedly binding to non-small-cell lung carcinoma and exerting potent therapeutic efficacyJian Xu, Yue Du, Xiu-Jun Liu, et al.
Pageof 4